Answers are grounded in this paper and cite their sources.
A 53-year-old woman with hormone receptor-positive breast cancer developed a localized erythematous vesicular eruption over her previously irradiated mastectomy site 7 days after completing adjuvant radiotherapy (4005 cGy in 15 fractions) and starting abemaciclib. Initial treatment with topical fusidic acid and corticosteroids was ineffective, and the rash worsened, leading to drug discontinuation (Figure 1). Rapid improvement occurred within 1 week of stopping abemaciclib. Upon rechallenge, the rash recurred within days and resolved again after cessation, confirming the radiation recall dermatitis (RDD) diagnosis (Figure 2). RDD is an uncommon but recognised adverse reaction in which systemic agents, particularly chemotherapeutics like taxanes or CDK4/6 inhibitors, trigger inflammation at previously irradiated sites [1, 2]. Unlike radiation dermatitis, RDD occurs after radiotherapy and follows drug exposure [3]. Recognition is essential to prevent misdiagnosis and to guide the safe reintroduction of critical oncologic therapies. In this case, the reaction was mild (grade 1–2), and resumption of abemaciclib with close monitoring was advised [4, 5]. C.Z. and Y.M. managed the case and drafted the manuscript. M.M. and A.P. contributed to data collection and clinical interpretation. G.T. provided radiological assessment. B.M.P. and M.S. supervised the work and critically revised the manuscript. All authors approved the final version. This study was funded by the University of Bologna. Open access publishing facilitated by Universita degli Studi di Bologna, as part of the Wiley - CRUI-CARE agreement. All patients in this manuscript have given written informed consent for participation in the study and the use of their deidentified, anonymized, aggregated data and their case details (including photographs) for publication. Ethical Approval: Not applicable. The authors declare no conflicts of interest. Data are available on request from the authors.
No takes yet. Share an insight, caveat, or question.
Zengarini et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: